Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital upgrades Intertek to 'hold' after recent sell-off

(Sharecast News) - Shore Capital has upgraded its rating on Intertek from 'sell' to 'hold' following a big fall in the share price of the testing services firm over the past month. As of Monday's close, shares had fallen around 20% since the release of Intertek's full-year results on 4 March, with the selling pressure intensifying over the past few days following the announcement of Donald Trump's sweeping trade tariffs.

"FY24A results were solid in our view, with our 'sell' recommendation reflecting our view of fair value and that future competition and margin sensitivities were not reflected," said analyst Robin Speakman.

"With the recent pull-back, we assess the immediate likely economic impacts on Intertek and reduce our forecasts. Our fair value falls from 4,600p to 4,500p, equating to 5% upside to the current share price."

Speakman said that Intertek - like all of its peers in the assurance, testing, inspection and certification (ATIC) sector - is "at the forefront of trade", with headwinds likely to remain a challenge across 2025 and into 2026.

"Beyond the medium-term, however, trade rules and compliance requirements will become re-established (likely stronger and more complex bilaterally), and this is likely to provide opportunities to our minds [...] ATIC service provision remains essential to the functioning of economies, and we continue to regard Intertek's operations accordingly in the long-term," the analyst said.

Intertek was trading 1.8% higher at 4,280p by 1358 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.